The global food allergy treatment market size was valued at USD 7,119 million in 2024 and is expected to hit around USD 15,773 million by 2034 with a CAGR of 8.28% from 2025 to 2034.
| Market Size value in 2025 | USD 7,708 Million |
| Revenue Forecast in 2034 | USD 15,773 Million |
| Growth Rate | CAGR of 8.28% from 2025 to 2034 |
| Segments Covered: | Drug type, allergen type, route of administration, end use, region |
| Key Companies | Sanofi; Stallergenes Greer; DBV Technologies; Vedanta Biosciences, Inc.; Alladapt Immunotherapeutics, Inc.; COUR Pharmaceuticals; Aravax; Prota Therapeutics; F. Hoffman-La Roche Ltd.; Novartis AG; Teva Pharmaceuticals |
The food allergy treatment market has experienced significant growth due to the rising prevalence of food allergies, increasing awareness among consumers and healthcare professionals, and advancements in diagnostic and therapeutic technologies. The market is driven by the need for effective diagnosis, management, and treatment of food allergies to improve patient outcomes and quality of life. Factors such as changes in dietary habits, environmental influences, and genetic predisposition contribute to the growing incidence of food allergies. The rising number of food allergy cases has led to increased demand for diagnostic tests and allergy management solutions. Food allergy is a condition that causes unusual reactions in the body after consuming certain foods. Some common examples of foods that cause allergies in individuals are peanuts, milk, eggs, fish, shellfish, wheat, soy, and sesame.
The growing awareness of food allergies and their potential health impacts has also played a crucial role in the growth of the food allergy treatment market. Public health campaigns, educational initiatives, and advocacy efforts have raised awareness about food allergies and the importance of accurate diagnosis and management. This increased awareness has led to greater demand for allergy testing, allergen-free foods, and medical treatments. Advancements in diagnostic and therapeutic technologies have influenced the food allergy treatment market. New diagnostic tools, such as component-resolved diagnostics and molecular allergology, offer more precise identification of allergens and better risk assessment. Additionally, ongoing research and development in immunotherapy, such as oral immunotherapy (OIT) and epicutaneous immunotherapy (EPIT), are exploring new treatment options to desensitize patients to allergens.
According to the American College of Allergy, Asthma, and Immunology, approximately 6% to 8% of children under three years of age and 3% of the global adult population suffer from food allergies. It involves an immunogenic response to particular foods, including peanuts, shellfish, nuts, and fish in adults and peanuts, tree nuts, eggs, wheat, and soy in children. The condition is much more severe in children unaware of how to avoid such allergens, and it can produce an allergic reaction very quickly. The painful symptoms associated with food allergies and the high incidence of anaphylaxis cause anxiety regarding food items, particularly in children who fear allergen exposure. The rising prevalence of various forms of allergies is estimated to enhance the market's growth.
Another significant factor influencing the growth rate of the food allergy treatment market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aim to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics. Due to compromised immune systems in geriatrics, they are more susceptible to different allergies, which is driving demand for anti-allergy treatments. Furthermore, rising initiatives by public and private organizations to spread awareness will expand the market. Additionally, the changing lifestyle of people and growing investment by manufacturers in the development of new allergic treatments will result in the expansion of the food allergy treatment market.
On the other hand, the high cost associated with the treatment will obstruct the growth rate of the market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the food allergy treatment market. Additionally, the rising use of low-cost biosimilars and lack of awareness among people about allergy immunotherapy will act as a restraint and further impede the growth rate of the market during the forecast period.
The advent of advanced technologies such as artificial intelligence and machine learning drives the latest innovations in food allergy treatment. These new technologies can revolutionize the way food allergies are diagnosed and treated. Artificial intelligence trained on images is being used to analyze food ingredient lists to detect the presence of any of the top nine food allergens, alerting individuals about the same. It can also create customized food alerts based on an individual’s dietary preferences and medical records. AI-enabled wearable devices and sensors can track allergen exposure, monitor symptoms, and provide real-time alerts in case of anaphylaxis. Moreover, machine learning is also helping transform research and development activities for novel drugs, speeding up clinical trials as well as drug discovery protocols. They can facilitate the development of personalized medicine based on individual needs. This ultimately improves the efficiency, accuracy, and precision of treatment regimens.
The growing research and development activities to develop novel ways to treat food allergies present future food allergy treatment market growth opportunities. Several researchers are investigating different treatment regimens for treating food allergies. Some novel approaches include allergen immunotherapy, DNA or viral-like particle vaccines, biologics such as anti-IgE antibodies as well as cell and gene therapy. The growing demand for biologics and regenerative medicine promotes the development of novel drugs. The increasing investments and public-private partnerships potentiate the market, and technological advancements also favor advanced R&D activities. Apart from developing novel drugs, animal models are also developed to study the safety and effectiveness of drugs. Animal models are combined with biomarker panels, advanced in vitro platforms, and state-of-the-art methods such as physiological-like elastic hydrogels and nanotextured 3D systems.
Published by Kesiya Chacko
